Patient profiles in which the use of fixed-does perindopril/indapamide gives additional benefit Review article
Article Sidebar
Published:
Sep 30, 2016
Keywords:
arterial hypertension, fixed-dose combination, perindopril, indapamide
Main Article Content
Abstract
Perindopril/indapamide fixed-dose combination (FDC) is not only drug formulation with proven hypotensive properities, it is also and FDC with additional benefits for a broad spectrum of patients. Many patients, whom we often meet in everyday practice gain additional benefit from using perindopril/indapamide FDC. Example of such patients include: elderly, patients with arterial hypertension and concomitant diabetes mellitus or chronic kidney disease, or patients with prior stroke. Below we introduce examples of clinical profiles of patients being perfect candidates for perindopril/indapamide treatment, as well as scientific evidence proving advantages of this kind of treatment.
Article Details
How to Cite
Płatek , A. E., & Szymański , F. M. (2016). Patient profiles in which the use of fixed-does perindopril/indapamide gives additional benefit. Medycyna Faktow (J EBM), 9(3(32), 224-230. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2225
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Mancia G., Fagard R., Narkiewicz K. et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013; 34(28): 2159-2219.
2. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Arterial Hypertens. 2015; 19: 53-58.
3. Beckett N.S., Peters R., Fletcher A.E. et al.: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358: 1887-1898.
4. Matheson A.J., Cheer S.M., Goa K.L.: Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension. Drugs 2001; 61(8): 1211-1229.
5. Gupta A.K., Arshad S., Poulter N.R.: Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55(2): 399-407.
6. Luccioni R., Sever P.S., Di Perri T. et al.: An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension. J. Hypertens. 1995; 13(12 Pt 2): 1847-1851.
7. Nedogoda S.V., Marchenko I.V., Chaliabi T.A. et al.: Comparative efficacy of fixed dose combinations of perindopril with indapamide and captopril with hydrochlorothiazide in patients with high risk hypertension. Kardiologiia. 2005; 45(11): 24-26.
8. Karnes J.H., Gong Y., Pacanowski M.A. et al.: Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenet. Genomics 2013; 23(12): 697-705.
9. Ambrosioni E., Safar M., Degaute J.P. et al.: Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. J. Hypertens. 1998; 16(11): 1677-1684.
10. ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
11. Zoungas S., Chalmers J., Neal B.; ADVANCE-ON Collaborative Group: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 2014; 371(15): 1392-1406.
12. Farsang C.: Efficacy and Tolerability of Fixed-Dose Combination of Perindopril/Indapamide in Type 2 Diabetes Mellitus: PICASSO Trial. Adv. Ther. 2014; 31(3): 333-344.
13. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
14. Tzourio C., Anderson C., Chapman N. et al.; PROGRESS Collaborative Group: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med. 2003; 163(9): 1069-1075.
15. Arima H., Anderson C., Omae T. et al.; PROGRESS Collaborative Group: Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial. J. Neurol. Neurosurg. Psychiatry 2014; 85(11): 1284-1285.
16. Lambers Heerspink H.J., Ninomiya T., Perkovic V. et al.; for the ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur. Heart J. 2010; 31: 2888-2896.
17. Meyrier A., Dratwa M., Sennesael J. et al.: Fixed low-dose perindopril-indapamide combination in hypertensive patients with chronic renal failure. Am. J. Hypertens. 1998; 11: 1087-1092.
2. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Arterial Hypertens. 2015; 19: 53-58.
3. Beckett N.S., Peters R., Fletcher A.E. et al.: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358: 1887-1898.
4. Matheson A.J., Cheer S.M., Goa K.L.: Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension. Drugs 2001; 61(8): 1211-1229.
5. Gupta A.K., Arshad S., Poulter N.R.: Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55(2): 399-407.
6. Luccioni R., Sever P.S., Di Perri T. et al.: An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension. J. Hypertens. 1995; 13(12 Pt 2): 1847-1851.
7. Nedogoda S.V., Marchenko I.V., Chaliabi T.A. et al.: Comparative efficacy of fixed dose combinations of perindopril with indapamide and captopril with hydrochlorothiazide in patients with high risk hypertension. Kardiologiia. 2005; 45(11): 24-26.
8. Karnes J.H., Gong Y., Pacanowski M.A. et al.: Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenet. Genomics 2013; 23(12): 697-705.
9. Ambrosioni E., Safar M., Degaute J.P. et al.: Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. J. Hypertens. 1998; 16(11): 1677-1684.
10. ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
11. Zoungas S., Chalmers J., Neal B.; ADVANCE-ON Collaborative Group: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 2014; 371(15): 1392-1406.
12. Farsang C.: Efficacy and Tolerability of Fixed-Dose Combination of Perindopril/Indapamide in Type 2 Diabetes Mellitus: PICASSO Trial. Adv. Ther. 2014; 31(3): 333-344.
13. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
14. Tzourio C., Anderson C., Chapman N. et al.; PROGRESS Collaborative Group: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med. 2003; 163(9): 1069-1075.
15. Arima H., Anderson C., Omae T. et al.; PROGRESS Collaborative Group: Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial. J. Neurol. Neurosurg. Psychiatry 2014; 85(11): 1284-1285.
16. Lambers Heerspink H.J., Ninomiya T., Perkovic V. et al.; for the ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur. Heart J. 2010; 31: 2888-2896.
17. Meyrier A., Dratwa M., Sennesael J. et al.: Fixed low-dose perindopril-indapamide combination in hypertensive patients with chronic renal failure. Am. J. Hypertens. 1998; 11: 1087-1092.